CIK 0001739174 · Non-accelerated filer<br>Smaller reporting company
Tessera Defense & Homeland Security Inc.
Sign in to watch- Ticker
- HLSQ
- Exchange
- NYSE
- Industry
- Services-Prepackaged Software
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 823364020
- Phone
- 972 545610935
- Business address
- 850 NEW BURTON ROAD, SUITE 201, DOVER, DE, 19904
- Former names
- BiomX Inc., Chardan Healthcare Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 32 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-29 | Oron Assaf Chief Business Officer | Returned to the company · Common Stock Options - Right to Buy | −82,667 | 0 | ||
| 2023-10-29 | Oron Assaf Chief Business Officer | Grant or award · Common Stock Options - Right to Buy | +82,667 | 0 | ||
| 2023-10-29 | Oron Assaf Chief Business Officer | Returned to the company · Common Stock Options - Right to Buy | −46,966 | 0 | ||
| 2023-10-29 | Oron Assaf Chief Business Officer | Grant or award · Common Stock Options - Right to Buy | +46,966 | 0 | ||
| 2023-10-19 | Williams Eddie Director | Grant or award · Common Stock Options - Right to Buy | +41,000 | 41,000 | ||
| 2023-08-21 | Marks Jason M. Director | Grant or award · Common Stock Options - Right to Buy | +41,000 | 41,000 | ||
| 2023-08-21 | Dambach Michael E. Director | Grant or award · Common Stock Options - Right to Buy | +41,000 | 41,000 | ||
| 2023-05-22 | Oron Assaf Chief Business Officer | Purchase | +3,192 | $0.27 | $872 | 10,914 |
| 2023-05-19 | Oron Assaf Chief Business Officer | Purchase | +6,521 | $0.28 | $2K | 7,722 |
| 2023-05-18 | Oron Assaf Chief Business Officer | Purchase | +1,201 | $0.27 | $328 | 1,201 |
| 2023-03-01 | Greig Russell Director | Grant or award · Common Stock Options - Right to Buy | +82,000 | 82,000 | ||
| 2023-03-01 | Moses Alan Charles Director | Grant or award · Common Stock Options - Right to Buy | +41,000 | 41,000 | ||
| 2023-03-01 | Bassan Merav Chief Development Officer | Grant or award · Common Stock Options - Right to Buy | +100,000 | 100,000 | ||
| 2023-03-01 | Wolfson Marina Chief Financial Officer | Grant or award · Common Stock Options - Right to Buy | +100,000 | 100,000 | ||
| 2023-03-01 | Sullivan Lynne Marie Director | Grant or award · Common Stock Options - Right to Buy | +41,000 | 41,000 | ||
| 2023-03-01 | Solomon Jonathan Eitan Chief Executive Officer | Grant or award · Common Stock Options - Right to Buy | +410,000 | 410,000 | ||
| 2023-03-01 | Oron Assaf Chief Business Officer | Grant or award · Common Stock Options - Right to Buy | +50,000 | 50,000 | ||
| 2023-02-27 | OrbiMed Israel BioFund GP Limited Partnership 10% owner | Purchase | +348,000 | $0.25 | $85K | 3,161,489 |
| 2023-02-27 | OrbiMed Israel BioFund GP Limited Partnership 10% owner | Purchase · Warrants (Right to Buy) | +1,789,959 | 1,789,959 | ||
| 2022-11-04 | Ugwumba Chidozie Exit Form 4 - former 10% owner | Sale | −1,501 | $0.38 | $567 | 2,997,025 |
Page 7 of 12 · 240 trades